Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Financial Officer | June 18, 2026 | June 23, 2026 |
| LogicBio Therapeutics, Inc.LOGC · Entity 122292 | Chief Financial Officer | March 01, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance share unitsSEC Table II · derivative / convertible security | Direct | 9,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Disposed 3,000 · Balance 9,000 F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 3,000 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 3,000 · Balance 3,000 F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
LogicBio Therapeutics, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2032-03-01 | Direct | 112,000 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 112,000 · Balance 112,000 F1: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan. F2: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan.
F2: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000083 · wk-form4_1782249240.xml · derivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000083 · wk-form4_1782249240.xml · derivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000063 · wk-form4_1775506133.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Underlying: Common stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,141 | $34.71 | $109,024.11 |
DisclosureSEC source: 0001439222-26-000063 · wk-form4_1775506133.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,998 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000063 · wk-form4_1775506133.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 311 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · derivative · entry 14 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,607 Underlying: Common stock · 5,303 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F9 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · derivative · entry 13 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: Common stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F9 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · derivative · entry 12 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,667 Underlying: Common stock · 5,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F8 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · derivative · entry 11 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F7 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,573 | $28.96 | $45,554.08 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 8 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,328 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 7 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,187 | $28.96 | $34,375.52 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 6 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,598 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 5 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,681 | $28.96 | $48,681.76 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 4 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,785 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 594 | $28.96 | $17,202.24 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,800 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 52,000 | $0.00 Strike: $30.23 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · derivative · entry 10 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,000 Underlying: Common stock · 52,000 shares Expires 2036-03-01 F6 · derivative.exercise_date: This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000038 · wk-form4_1772572487.xml · derivative · entry 9 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Underlying: Common stock · 14,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| December 30, 2025 Filed Jan 3, 2026 01:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000002 · wk-form4_1767402864.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| December 30, 2025 Filed Jan 3, 2026 01:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,932 | $27.09 | $79,427.88 |
DisclosureSEC source: 0001439222-26-000002 · wk-form4_1767402864.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,394 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023. Read SEC document |
| December 30, 2025 Filed Jan 3, 2026 01:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000002 · wk-form4_1767402864.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 456 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 21:56 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 7,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000104 · wk-form4_1759269358.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 7,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units vest in three equal annual installments. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 21:56 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,651 | $36.77 | $134,247.27 |
DisclosureSEC source: 0001439222-25-000104 · wk-form4_1759269358.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,870 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 26, 2022. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 21:56 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 7,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000104 · wk-form4_1759269358.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000067 · wk-form4_1750973073.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Common stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,780 | $33.54 | $59,701.20 |
DisclosureSEC source: 0001439222-25-000067 · wk-form4_1750973073.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,049 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000067 · wk-form4_1750973073.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,681 | $35.54 | $59,742.74 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · nonDerivative · entry 4 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,829 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 594 | $35.54 | $21,110.76 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,843 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · derivative · entry 9 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,333 Underlying: Common stock · 5,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F8 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · derivative · entry 8 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Underlying: Common stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F7 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 43,500 | $0.00 Strike: $35.54 | $0.00 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · derivative · entry 7 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,500 Underlying: Common stock · 43,500 shares Expires 2035-03-01 F6 · derivative.exercise_date: This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 15,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · derivative · entry 6 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,910 Underlying: Common stock · 15,910 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · derivative · entry 5 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · nonDerivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000019 · wk-form4_1741122903.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 279 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 7,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000129 · wk-form4_1727727323.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,472 Underlying: Common stock · 7,473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,542 | $49.03 | $124,634.26 |
DisclosureSEC source: 0001439222-24-000129 · wk-form4_1727727323.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,158 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 26, 2022. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 7,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000129 · wk-form4_1727727323.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,329 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 672 | $32.57 | $21,887.04 |
DisclosureSEC source: 0001439222-24-000052 · wk-form4_1709673462.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,840 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000052 · wk-form4_1709673462.xml · derivative · entry 5 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Underlying: Common stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F6 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 60,000 | $0.00 Strike: $32.27 | $0.00 |
DisclosureSEC source: 0001439222-24-000052 · wk-form4_1709673462.xml · derivative · entry 4 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common stock · 60,000 shares Expires 2034-03-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000052 · wk-form4_1709673462.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,000 Underlying: Common stock · 17,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000052 · wk-form4_1709673462.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 942 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| January 24, 2024 Filed Jan 24, 2024 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,886 | $21.64 | $40,813.04 |
DisclosureSEC source: 0001439222-24-000018 · wk-form4_1706131387.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,069 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 26, 2022. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000018 · wk-form4_1706131387.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on September 26, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on September 26, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000018 · wk-form4_1706131387.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2023 Filed Sep 28, 2023 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,179 | $24.79 | $54,017.41 |
DisclosureSEC source: 0001439222-23-000133 · wk-form4_1695931360.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,575 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated 9/28/23. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 7,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000133 · wk-form4_1695931360.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,945 Underlying: Common stock · 7,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.